in vitro  studies show ensovibep (MP0420) maintains full potency against the known mutations of SARS-CoV-2, including those present in variants first identified in Brazil, California, India, and New York, in addition to the previously reported variants originating from the UK and South Africa

Zurich-Schlieren, Switzerland, May 04, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021.

Zurich-Schlieren, Switzerland, April 23, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has filed a registration statement on Form F-1 with the

Zurich-Schlieren, Switzerland, April 21, 2021.  At today’s AGM of  Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of

Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression.

First study of ensovibep in patients with symptomatic COVID-19 disease Designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep Ensovibep is additionally planned to be tested in two global, placebo controlled, double blinded trials: A Phase 2-3 trial in an

Zurich-Schlieren, Switzerland, March 26, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today   published the invitation to the Annual General Meeting 2021.

Pharmaceutical industry expert with extensive knowledge of R&D and commercialization Zurich-Schlieren, Switzerland, March 25, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics,

Zurich-Schlieren, Switzerland, March 22, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it plans to conduct a registered public offering of its ordinary

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3 Clinical trial includes an interim analysis after 300 patients